What's Next For Roivant? It's Not More Publicly Traded "Vants"
Roivant is focused on expanding its existing subsidiaries, building new ones and appointing top leadership teams to run them, but founder and CEO Vivek Ramaswamy has put a hold on more IPOs.
You may also be interested in...
Roivant subsidiary thinks EMPOWUR data would position the drug as best-in-class in overactive bladder, but investors responded to the data with a clear thumbs-down.
In tandem with Roivant, Cincinnati Children’s launches spinout Aruvant focused on hematologic disorders and separately teams with BridgeBio on genetic disease therapies. Roivant spinout Axovant licenses gene therapy candidates from University of Massachusetts.
With biopharma venture capital investment of $9.67bn during the first half, 2018's total is on track to beat 2017 in the third quarter. IPOs, one of the factors fueling VC investment, continue to boom with five more drug developers slated to go public this week.